| Literature DB >> 32714846 |
Mehmet Diyaddin Güleken1, Taner Akbaş2, Selime Çelik Erden2, Veysel Akansel3, Zeliha Cengiz Al4, Ömer Akil Özer2.
Abstract
•Despite their major effects on positive symptoms, antipsychotics do not have a significant effect on cognition in schizophrenia•Bilateral high frequency rTMS targeting dorsolateral prefrontal cortices has been effective on working memory•Bilateral 20 Hz rTMS improved attention and verbal working memory in schizophrenia patients,•It also improved the competence of switching the perceptional set up under a disruptive effect towards new instructions, in this study.Entities:
Year: 2020 PMID: 32714846 PMCID: PMC7371913 DOI: 10.1016/j.scog.2020.100183
Source DB: PubMed Journal: Schizophr Res Cogn ISSN: 2215-0013
Fig. 1Flow diagram.
Demographic and clinical data.
| Healthy (n = 11) | Active (n = 11) | Sham (n = 10) | ||
|---|---|---|---|---|
| Mean age (years) | 36.55 ± 8.80 | 36.45 ± 8.58 | 34.40 ± 12.11 | .857 |
| Gender (M/F) | 8/3 | 8/3 | 6/4 | .725 |
| Mean years of education, n | 10.64 ± 1,50 | 10.73 ± 1.61 | 10.60 ± 1.89 | .984 |
| Mean duration of illness (months) | – | 184.55 ± 97.51 | 133.10 ± 120.77 | .078 |
| Number of inpatient treatments | – | 4.64 ± 4.24 | 3.50 ± 3.44 | .476 |
| PANSS/SANS scores | – | 81.82 ± 8.94/52.64 ± 13.14 | 79.70 ± 7.61/43.10 ± 15.50 | .568/.144 |
| Chlorpromazine equivalent dose of antipsychotic drugs (mg) | – | 845.45 | 661.66 | .318 |
| Type of antipsychotic drug (typical vs. atypical) | – | Typical = 1 | Typical = 0 | .648 |
| Medication, n: dose (mg) | ||||
| Haloperidol | – | n = 2 (20 mg/day, 50 mg/week dekanoat) | n = 1 (10 mg/day) | |
| Zuclopentixol | – | n = 1 (200 mg/2 week depot) | – | |
| Flupentixol | – | – | n = 1 (20 mg/2 week depot) | |
| Chlorpromazine | – | n = 1 (100 mg/day) | – | |
| Risperidone | – | n = 4 (2 × 3 mg/day, 2 × 50 mg/2 week consta) | n = 3 (2 mg/day, 2 × 50 mg/2 week consta) | |
| Paliperidone | – | – | n = 3 (6 mg/day, 100 mg/4 week and 150 mg/4 week injection) | |
| Amisulpiride | – | n = 1 (800 mg/day) | – | |
| Clozapine | – | n = 2 (2 × 600 mg/day) | n = 4 (2 × 200 mg/day, 400 mg/day, 500 mg/day) | |
| Olanzapine | – | n = 2 (10 mg/day, 15 mg/day) | n = 1 (5 mg/day) | |
| Quetiapine | – | n = 5 (3 × 300 mg/day, 400 mg/day, 600 mg/day) | n = 2 (50 mg/day, 300 mg/day) | |
| Aripiprazole | – | n = 2 (2 × 30 mg/day) | n = 3 (15 mg/day, 2 × 30 mg/day) |
Demographic and clinical data ± SD of healthy control and active and sham rTMS schizophrenia groups. PANSS = Positive and Negative Syndrome Scale; rTMS = repetitive transcranial magnetic stimulation; SANS = Scale for the Assessment of Negative Symptoms.
Comparison of baseline test scores between healthy control group and each of schizophrenia treatment group.a
| Performance | Active (n = 11) | Healthy (n = 11) | Sham (n = 10) |
|---|---|---|---|
| WCST scores ( | |||
| Total trials administered | 1.000 | 0.717 | |
| Correct responses | |||
| Incorrect responses | |||
| Perseverative responses | 0.266 | ||
| Perseverative errors | 0.159 | ||
| Nonperseverative errors | 0.092 | 0.127 | |
| % of perseverative errors | 0.156 | ||
| Categories | |||
| Trials to complete the first category | 0.806 | 0.513 | |
| % of conceptual level responses | |||
| Failure to maintain set | 0.400 | 0.974 | |
| Learning to learn | 0.493 | 0.651 | |
| ST scores ( | |||
| Total time | |||
| Total errors | 1.000 | 0.453 | |
| Interference | 0.060 | ||
| DST scores ( | |||
| Forward span | 0.462 | 0.120 | |
| Backward span | 0.555 |
DST = Digit Span Task; ST = Stroop Test; WCST = Wisconsin Card Sorting Test.
Bold data indicate significance at p < 0.05.
One-Way ANOVA test.
Comparison of pre- and post-treatment ST scores in between schizophrenia treatment groups.
| Performance | Active (n = 11) | Sham (n = 10) | ||
|---|---|---|---|---|
| Pre-treatment | ||||
| Total time | 208.31 ± 40.89 | 210.34 ± 30.55 | .899 | |
| Total errors | 1.09 ± 2.46 (0) | 4.00 ± 7.10 (5) | .154 | |
| Interference | 60.307 ± 23.41 | 64.09 ± 16.29 | .680 | |
| Post-treatment | ||||
| Total time | 177.32 ± 22.52 | 202.22 ± 30.29 | ||
| Total errors | 0.45 ± 1.21 (0) | 2.60 ± 2.98 (2) | ||
| Interference | 44.44 ± 10.33 | 61.08 ± 19.02 |
ST = Stroop Test.
Bold indicate significant value.
Student t-test.
Mann-Whitney U test.
Comparison of pre- and post-treatment DST scores between schizophrenia treatment groups.a
| Performance | Active (n = 11) | Sham (n = 10) | ||
|---|---|---|---|---|
| Pre-treatment | ||||
| DST forward (mean ± SD; median) | 5.73 ± 0.90 (6) | 5.30 ± 1.05 (5) | .269 | |
| DST backward (mean ± SD; median) | 4.00 ± 0.63 (4) | 3.40 ± 0.96 (4) | .125 | |
| Post-treatment | ||||
| DST forward (mean ± SD; median) | 5.91 ± 0.94 (6) | 5.10 ± 0.56 (5) | ||
| DST backward (mean ± SD; median) | 4.36 ± 0.50 (4) | 3.70 ± 0.82 (4) |
DST = Digit Span Task.
Bold indicate significant value.
Mann-Whitney U test.
Intra-group changes in ST and DST scores in active rTMS group.
| Performance | Time | Test score (mean ± SD; median) | ||
|---|---|---|---|---|
| ST scores | ||||
| ST total time | Pre-treatment | 208.31 ± 40.89 (194.39) | ||
| Post-treatment | 177.32 ± 22.52 (171.08) | |||
| ST total errors | Pre-treatment | 1.09 ± 2.46 (0) | .414 | |
| Post-treatment | 0.45 ± 1.21 (0) | |||
| Interference | Pre-treatment | 60.37 ± 23.41 (57.89) | ||
| Post-treatment | 44.44 ± 10.33 (41.39) | |||
| DST scores | ||||
| DST forward | Pre-treatment | 5.73 ± 0.90 (6) | .480 | |
| Post-treatment | 5.91 ± 0.94 (6) | |||
| DST backward | Pre-treatment | 4.00 ± 0.63 (4) | ||
| Post-treatment | 4.36 ± 0.50 (4) |
DST = Digit Span Task; ST = Stroop Test.
Bold indicate significant value.
Paired samples t-test.
Wilcoxon test.